Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD206 CAR T cells
- Development stage
- Preclinical
- Lead developer
- Celdara Medical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intradermal, Intravenous
01
Overview
Anti-CD206 CAR T cells are an experimental, preclinical autologous chimeric antigen receptor (CAR) T-cell therapy designed to target and eliminate CD206-high (CD206+) profibrotic macrophages. Developed by researchers at Dartmouth College in collaboration with Celdara Medical, this second-generation CAR T-cell construct (anti-CD206-CD8TM-CD28-CD3zeta) utilizes a camelid-derived single-domain antibody (nanobody) targeting CD206 (macrophage mannose receptor, MRC1) fused to mouse CD28 hinge, transmembrane, and intracellular signaling domains, and a CD3zeta signaling domain. In preclinical models of systemic sclerosis (SSc), a single systemic dose of these CAR T cells successfully restored dermal white adipose tissue (DWAT) lost to fibrosis and reduced dermal thickness. Mechanistic studies suggest that CD206-high macrophages drive systemic sclerosis pathology by redirecting the lineage commitment of adipose-derived stem cells (ADSCs) from adipocytes toward myofibroblasts via an IL-6-dependent pathway.
- Other names
- anti-CD206 CAR-T cellsanti-CD-206 CAR-T cellsanti-CD 206 CAR-T cellsanti-CD206-CD8TM-CD28-CD3zetaanti-CD-206-CD8TM-CD28-CD3zetaanti-CD 206-CD8TM-CD28-CD3zetaanti-CD206-CD8TM-CD28-CD3zeta CAR T cellsanti-CD-206-CD8TM-CD28-CD3zeta CAR T cellsanti-CD 206-CD8TM-CD28-CD3zeta CAR T cells
02
Targets
IL-6 (Interleukin 6)IL-6R (Interleukin-6 receptor subunit alpha)MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on anti-CD206 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD206 CAR T cells.